From 13 till 17 September 2024: HIGHLIGHTS FROM ESMO
Your direct line with Barcelona
The European Society of Medical Oncology (ESMO) 2024 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Barcelona, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
Presidential highlights
Daily highlights in lung cancer
Prof Mariana Brandão, medical oncologist at the Institut Jules Bordet in Brussels shares a selection of studies presented during the mini oral session of NSCLC that she had the honour
Prof Dr Lore Decoster, a thoracic oncologist at UZ Brussels, provided an analysis of several abstracts presented during the second mini-oral session on NSCLC.
An updated analysis of the
Dr Dieter Stevens. thoracic oncologist at Ghent University Hospital discusses a selection of abstracts that were presented during the mini oral session on non-metastatic NSCLC.
Neoadjuvant and perioperative immunotherapy
In this video, Prof Dr Johan Vansteenkiste, a thoracic oncologist at the University Hospitals Leuven, discusses a selection of abstracts presented during the proffered paper session on non-metastatic lung cancer
The proffered paper session on metastatic non-small cell lung cancer (NSCLC) at ESMO 2024 focussed on three main topics: immune checkpoint inhibitor (ICI) combinations, the management of EGFR-mutant NSCLC after
In-depth stories about lung cancer
Prof Mariana Brandão, medical oncologist at Institut Jules Bordet and Prof Martin Reck, pulmonologist at the German Center for Lung Research, discussed the expanded analysis of the AEGEAN trial, evaluating
Dr Stefan Rauh, a medical oncologist at Centre Hospitalier Emile Mayrisch in Luxembourg, discusses targeted therapy for BRAFV600E-mutant metastatic NSCLC, found in about 1-3% of cases. This mutation, significant in
In this video, Prof Dr Mariana Brandao (Institut Jules Bordet, Brussels, Belgium) and Prof Dr Sanjay Popat (Royal Marsden Hospital, London, UK) summarize the results of this updated analysis and
Prof Nicolas Girard, thoracic oncologist at Institut Curie, Paris, presented data from the Relativity 104 trial, which evaluated nivolumab plus relatlimab and chemotherapy versus nivolumab plus chemotherapy as a first-line
Prof Mariana Brandão, medical oncologist at the Institut Jules Bordet, Brussels, discusses resistance mechanisms to amivantamab and o simertinib with prof Benjamin Besse, medical oncologist at Institut Gustave Roussy, Paris,
Lung cancer poster selection
The research project of Dr Elena Donders (University Hospitals Leuven, Leuven, Belgium) evaluates whether the composition of metastatic lymph nodes (mLN) can influence or even predict a response to immunotherapy
The design of this trial was presented as a poster by Dr Maximilian Hochmair (Klinik Floridsdorf, Vienna, Austria) during the 2024 annual ESMO meeting.
Since the publication of the PACIFIC trial, chemoradiotherapy followed by consolidation durvalumab has become standard of care for patients with unresectable, stage III non-small cell lung cancer (NSCLC). Subsequently, the
Made possible with the financial support of our partners.
All videos are developed independently and are non-promotional.
